Angiopoietin and Adverse Outcomes in Cardiac Surgery

Centre Hospitalier Universitaire, Amiens200 enrolled

Overview

Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery. The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

200

Conditions

Cardiac Surgery Acute Kidney Injury

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * adult patient scheduled for cardiac surgery under cardiopulmonary bypass Exclusion Criteria: * patient less than 18 years old, * redo surgery, * urgent surgery, * endocarditis, * aortic root repair surgery * aortic dissection * heart beating surgery, * heart transplantation

Outcomes

Primary Outcomes

Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of major cardiovascular event

major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death

Time frame: 28 days

correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and occurence of major cardiovascular event

major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death

Time frame: 28 days

Secondary Outcomes

Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of postoperative pulmonary complications

Time frame: 28 days

Correlation between abnormal angiopoietin 2 concentration (ng/ml) and number of postoperative pulmonary complications

Time frame: 28 days

Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 3 months

Time frame: 3 months

Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality at 3 months

Time frame: 3 months

Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 6 months

Time frame: 6 months

Correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and mortality at 6 months

Time frame: 6 months

Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality rate at 12 months

Time frame: 12 months

Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality rate at 12 months

Time frame: 12 months

Angiopoietin and Adverse Outcomes in Cardiac Surgery

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts